GTS Securities LLC Lowers Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

GTS Securities LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 86.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,877 shares of the biopharmaceutical company's stock after selling 86,807 shares during the period. GTS Securities LLC's holdings in Gilead Sciences were worth $1,282,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bartlett & CO. Wealth Management LLC raised its stake in shares of Gilead Sciences by 149.1% during the 4th quarter. Bartlett & CO. Wealth Management LLC now owns 8,697 shares of the biopharmaceutical company's stock worth $803,000 after purchasing an additional 5,205 shares during the period. Avior Wealth Management LLC increased its holdings in Gilead Sciences by 33.2% during the fourth quarter. Avior Wealth Management LLC now owns 12,551 shares of the biopharmaceutical company's stock worth $1,140,000 after buying an additional 3,129 shares during the last quarter. Brighton Jones LLC raised its position in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after acquiring an additional 2,450 shares during the period. RFG Advisory LLC boosted its stake in Gilead Sciences by 4.4% in the fourth quarter. RFG Advisory LLC now owns 13,910 shares of the biopharmaceutical company's stock valued at $1,285,000 after acquiring an additional 581 shares during the last quarter. Finally, Pflug Koory LLC grew its position in shares of Gilead Sciences by 7.5% during the 4th quarter. Pflug Koory LLC now owns 2,143 shares of the biopharmaceutical company's stock valued at $198,000 after acquiring an additional 150 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GILD has been the topic of several research analyst reports. Bank of America upped their price objective on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a research report on Thursday, February 13th. Morgan Stanley boosted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target for the company. Finally, Wells Fargo & Company lifted their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $110.55.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $19,977,938.37. This trade represents a 9.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider now directly owns 121,152 shares in the company, valued at $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,929 shares of company stock valued at $5,644,780. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Price Performance

NASDAQ:GILD traded up $2.67 during midday trading on Thursday, hitting $111.11. The company had a trading volume of 5,591,682 shares, compared to its average volume of 7,714,383. The company has a market capitalization of $138.21 billion, a PE ratio of 300.30, a P/E/G ratio of 0.71 and a beta of 0.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The stock's fifty day moving average price is $105.36 and its 200-day moving average price is $100.57.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same period in the previous year, the business posted ($1.32) EPS. The business's quarterly revenue was down .3% on a year-over-year basis. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.